GlaxoSmithKline Pharmaceuticals Limited

NSE GLAXO.NS

GlaxoSmithKline Pharmaceuticals Limited Return on Assets (ROA) for the year ending March 31, 2024: 16.59%

GlaxoSmithKline Pharmaceuticals Limited Return on Assets (ROA) is 16.59% for the year ending March 31, 2024, a -9.64% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

GlaxoSmithKline Pharmaceuticals Limited Return on Assets (ROA) for the year ending March 31, 2023 was 18.36%, a 123.38% change year over year.
GlaxoSmithKline Pharmaceuticals Limited Return on Assets (ROA) for the year ending March 31, 2022 was 8.22%, a -28.56% change year over year.
GlaxoSmithKline Pharmaceuticals Limited Return on Assets (ROA) for the year ending March 31, 2021 was 11.50%, a 287.00% change year over year.
GlaxoSmithKline Pharmaceuticals Limited Return on Assets (ROA) for the year ending March 31, 2020 was 2.97%, a -73.90% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NSE: GLAXO.NS

GlaxoSmithKline Pharmaceuticals Limited

CEO	Mr. Bhushan Akshikar
IPO Date	July 1, 2002
Location	India
Headquarters	GSK House
Employees	3,211
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Vaccines

Description

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Key trends

Past 5 years